Note: Ingredients listed on restricted chemical lists
EC/CAS
25322-68-3
Name of the chemical
polyethyleneglycol
Concentration
>=20-<30 200-1540
General Information
Version
1.0
Revision date
2023-05-26
Product name
Bio-Mycin 200, solution for injection
Product Synonyms
Bio-Mycin® 200 (oxytetracycline injection); BIVATOP® 200
1.2.1 Relevant identified uses
Veterinary product
1.2.2. Uses advised against
Safety Data Sheet only for the professional user., For veteri- nary use only, Refer to the product insert for complete instruc- tions on usage
supplier name
Boehringer Ing. Pharma GmbH & Co. KG
Emergency telephone
+1 703-527-3887, +49800 1817059
Icons in SDS
Company Information
company name
Boehringer Ing. Pharma GmbH & Co. KG
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H317, H360
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
OSHA Hazards GHS classification in accordance with the
2.1 Classification of the substance or mixture
in accordance with the
Signal word
Danger
Hazard statements
H317 May cause an allergic skin reaction. H360 May damage fertility or the unborn child.
Prevention
P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P261 Avoid breathing mist or vapours. P272 Contaminated work clothing must not be allowed out of the workplace. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response
P302 + P352 IF ON SKIN: Wash with plenty of soap and water. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P333 + P313 If skin irritation or rash occurs: Get medical advice/ P363 Wash contaminated clothing before reuse.
Storage
P405 Store locked up.
Disposal
P501 Dispose of contents/ container to an approved waste dis- posal plant.
2.3 Other hazards
This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) The pharmacological effect of the medicament has to be considered (see package leaflet).
